The influence of intra-arterial infusion of arginine vasopressin on cochlear blood flow in the rat by McLaren, G. M. et al.
Hearing Resenrch, 55 (1991) l-8 
0 1991 Elsevier Science Publishers B.V. All rights reserved 0378-5955/91/$03.50 
HEARES 01595 
The influence of intra-arterial infusion of arginine vasopressin on 
cochlear blood flow in the rat 
G.M. McLaren ‘, J.K.M. Coleman ‘, W.S. Quirk *, H.A. Dengerink ’ and J.W. Wright ’ 
’ Department of Psychology, Washington State CJniLwsity, Pullman, Washington, U.S.A. and ’ Kresge Hearing Research Institute, The University of 
Michigan, Ann Arbor, Michigan, U.S.A. 
(Received 20 August 1990; accepted 13 February 1991) 
Intra-arterially infused arginine vasopressin (AVP) elevated systemic blood pressure (BP) in the Sprague-Dawley rat according to a 
dose-response pattern while cochlear blood flow (CoBF), as measured by laser Doppler flowmetry, was elevated only at the highest dose. Skin 
blood flow (SBFJ decreased significantly with AVP infusion. The local infusion of AVP into the anterior inferior cerebellar artery (AICA), which 
supplies the common cochlear artery, produced significant dose-dependent reductions in CoBF with no changes in systemic blood pressure. 
Pretreatment of the local cochlear supplying vessels with an AVP-specific V, receptor antagonist attenuated subsequent AVP-induced decreases 
in CoBF, thereby demonstrating specificity of the response. These results suggest that CoBF is reasonably stable in response to systemic AVP 
infusion until blood pressure exceeds an elevation from base level of approximately +60 mm Hg. One of the mechanisms responsible for this 
autoregulatory response may be vasoconstriction mediated by the interaction of vasoactive peptides such as AVP and its receptors located in the 
vasculature of the inner ear or in the more peripheral vessels directly supplying the cochlea. 
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Introduction 
The cochlea receives approximately l/10,000 of the 
total cardiac output (Short et al., 1985) primarily by 
way of the spiral modiolar artery (SMA). The spiral 
modiolar artery branches off the common cochlear 
artery which in turn is supplied by the labyrinthine, 
anterior inferior cerebellar (AICA), and basilar arter- 
ies, respectively (Axelsson and Vertes, 1978; Dengerink 
et al., 1987). Although much effort has been devoted to 
understanding the vascular anatomy of the cochlea 
(reviewed by Axelsson and Ryan, 1988; Ryan, 1988; 
Ryan et al. 1988), far less is known about the mecha- 
nisms that may control cochlear blood flow (CoBF). 
For instance, there is a paucity of information concern- 
ing neuropeptide-activated vascular receptor popula- 
tions in the cochlear vasculature which is the major 
focus of this investigation. 
Although sufficient increases in systemic blood pres- 
sure (BP) elevate CoBF (Goodwin et al., 1984; Miller 
et al., 1983, 1984; Snow and Suga, 1971; Wright et al., 
1985), it is clear that autoregulation of CoBF occurs 
under certain experimental conditions. For example, 
initial elevations in CoBF produced by intra-arterial 
infusions of angiotensin II (AU), epinephrine, or 
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phenylephrine, diminish and return toward base level 
despite sustained elevations in BP (Dengerink et al., 
1986; Miller et al., 1986; Quirk et al., 1988). These 
observations appear to fit the classic definition of blood 
flow autoregulation, viz., the ability of a tissue to 
maintain a constant blood flow in the presence of an 
altered perfusion pressure (Bayliss, 1902; Johnson, 1986 
for review). This autoregulatory pattern of CoBF dur- 
ing sustained elevations in systemic BP, suggests an 
active mechanism for moderating blood flow within the 
cochlea, and/or its supplying vessels. 
Recent work in our laboratory has revealed signifi- 
cant [ ‘*‘I]Sar ‘, Iles-AI1 receptor binding in the cochlear 
vasculature of young Sprague-Dawley (SD, Coleman, 
et al., submitted), Wistar-Kyoto (WKY), and sponta- 
neously hypertensive rats (SHR, Cook et al., submit- 
ted). Quirk et al. (1989) have reported dose-dependent 
decreases in CoBF during infusion of AI1 into the 
AICA, thus suggesting a potential physiological re- 
sponse mediated by this receptor population. Given 
that systemic and central infusions of AI1 have been 
reported to stimulate the release of the potent vaso- 
constrictor, arginine vasopressin (AVP, Bonjour and 
Malvin, 1976; Keil et al., 1984; Phillips, 1979, 1987; 
Sladeck et al., 1979), the present study evaluated the 
ability of AVP to influence CoBF when intra-arterially 
infused. We predicted that infusion of AVP into the 
carotid artery would yield increases in systemic blood 
pressure accompanied by no changes in CoBF (main- 
tained constant flow), and decreases in skin blood flow 
(SBF) in agreement with previous findings using All 
(Goodwin et al., 1984; Quirk et al., 1989; Wright et al., 
1985). The local infusion of AVP into the AICA was 
expected to produce dose-related reductions in CoBF 
with no significant alterations in systemic blood pres- 
sure. Pretreatment of the cochlear vasculature and its 
supplying vessels with an AVP-specific receptor antag- 
onist via the AICA, was predicted to block the subse- 
quent effects of local AVP infusion upon CoBF, thus 
establishing the specificity of this response to the AVP 
contractile system. Finally, it was predicted that femoral 
artery AVP infusion, following AICA AVP receptor 
antagonist infusion, would yield significant elevations 
in both systemic BP and CoBF since the vasoconstric- 
tive effects of AVP would be blocked in the cochlear 
vasculature. 
Method 
Animals and peptides 
Adult male Sprague-Dawley rats, derived from stock 
originally purchased from Charles River, weighing 
340-540 g (mean f SEM = 430 _+ 2 g) were utilized in 
these experiments. The animals were bred and housed 
in group cages in an American Association for Accred- 
itation of Laboratory Animal Care (AAALACJ-ap- 
proved vivarium under a 12:12 h light/dark cycle initi- 
ated at 0700 h at 22 (+ 1 o C with Purina rat chow and 
water available ad libitum. Arginine vasopressin (8103) 
and the V,-specific AVP receptor antagonist, 
d(CH ,),(Tyr)(Me)-AVP (8109) (Kruzynski et al., 1980) 
were purchased from Peninsula Laboratories (Be- 
lmont, CA). 
Surgery and instrumentation 
Each animal of Experiment 1 was anesthetized with 
Ketamine Hydrochloride (Bristol-Myers, and Co.) ac- 
companied by the muscle relaxant Xylazine (Haver and 
Co.) at doses of 100 and 2 mg/kg i.m., respectively. 
Body temperature was maintained at 38 f 1” C with a 
heating pad and monitored with a rectal thermistor 
(Yellow Springs Co. Model 43TK). The right common 
carotid artery was prepared with a flow-through 
catheter (PE-60, Clay Adams) designed to permit si- 
multaneous intra-arterial infusion and recording of sys- 
temic blood pressure (Quirk et al., 1989) via a Statham 
transducer (Model P23AC) and a Grass polygraph 
(Model 5D). The left bulla was exposed ventrally and 
opened to reveal the cochlea. The probe (0.9 mm 0.d.) 
of the laser Doppler flowmeter (Optokinetics Corp., 
Advanced Model ALF2100) was positioned on the 
cochlea via a micromanipulator (Stoelting Co., Model 
MM331 according to procedures described elsewhere 
(Goodwin et al., 1984; Wright et al., 198.5). Recently, 
LaRouere et al. (1989) reported good correlation be- 
tween laser Doppler and intravital microscopy mea- 
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Fig. 1. Inferior view of the exposed vasculature and the position of 
the 3-barrel glass capillary pipette in the basilar artery such that its 
infusion outflow entered the anterior inferior cerebellar artery. 
sures of regional cochlear blood flow. Additional ani- 
mals were similarly anesthetized and catheterized, 
however, hair was removed from the inner right thigh 
to permit skin blood flow measurement via the laser 
Doppler flowmeter. 
The animals that were used in Experiments 2 and 3 
to measure changes in BP and CoBF during the infu- 
sion of AVP via the AICA were prepared as above. In 
this case, however, a right femoral artery catheter 
(PE-50, Clay Adams) was utilized to measure BP and 
the basilar artery was ventrally exposed to permit infu- 
sion into the AICA via a triple-barrel pipette (Fig. 1). 
Additionally, a tracheostomy was performed on each 
animal to insure a clear airway. The pipettes used in 
these experiments had a total outside diameter of 20 
pm and each barrel was junctioned with PE-10 tubing 
attached to a 10 ~1 syringe (Hamilton, Model 701). 
Each syringe was driven by a microinfusion pump 
(Razel, Model A99) at a flow rate of 100 nl/min. Each 
barrel was preloaded with 0.15 M NaCl, AVP or the 
AVP antagonist. In a preliminary investigation 0.5% 
Evans blue dye in 0.15 M NaCl was infused so that the 
laminar flow could be visualized under a surgical mi- 
croscope. The position of the pipette tip was adjusted 
at the junction of the basilar artery and the AICA for 
optimum delivery of the infusant (Fig. 1). 
In Experiment 4, each animal was prepared with 
separate right and left femoral artery catheters to 
permit an uninterrupted measurement of systemic 
blood pressure and a separate infusion route. These 
animals were then prepared identically with those ani- 
mals participating in Experiments 2 and 3. In this 
experiment only two of the three barrels of each pipette 
were utilized, one barrel was preloaded with 0.15 M 
NaCl and the other with an AVP-specific receptor 
antagonist. 
Experiment 1: Effects of intra-arterial infusion of AVP 
on CoBF and SBF 
Forty-eight rats were randomly assigned to 6 groups 
(8 each). Base-level BP and CoBF were established 
during a 10 min pre-infusion period. Members of Group 
1 served as controls and received two lo-min infusions 
of 0.15 M NaCl (50 pl/min) via the flow-through 
catheter. These infusions were separated by 10 min. 
Four of the animals of Group 2 received a 10 min 
infusion of 0.15 M NaCl followed 10 min later by a 10 
min infusion of AVP at a dose of 0.1 pmol/50 ~1 0.15 
M NaCl/min. The other four animals of this group 
received the AVP infusion first and the 0.15 M NaCl 
second (i.e. a counter-balanced design). The animals in 
Groups 3-5 were treated equivalently to Group 2, 
however, AVP doses of 1, 10 and 100 pmol/50 ~1 0.15 
M NaCl/min were utilized, respectively. An additional 
group of 24 animals was used to assess the influence of 
intra-arterially infused AVP on skin blood flow. Sub- 
groups of 8 animals received 10 min infusions of 0.15 
M NaCl (50 pl/min) via the flow-through catheter, 
and one dose of AVP (1, 10 or 100 pmol/50 ~10.15 M 
NaCl/min). Within these subgroups, 4 animals re- 
ceived 0.15 M NaCl first and AVP second, while the 
other 4 animals received AVP first and 0.15 M NaCl 
second. A minimum of 10 min was permitted between 
treatments to recover base-level blood pressure and 
CoBF. Independent groups were used to examine each 
dose of AVP because of the long lasting pressor effects 
induced by AVP, particularly at the higher doses. 
Experiment 2: Anterior inferior cerebellar artery 
(AICA) AVP infusion 
Twenty-four animals were assigned to 3 groups (8 
each) and received two 10 min AICA infusions (100 
nl/min), separated by at least 10 min. Group 1 animals 
received two infusions of 0.15 M NaCl and served as 
control animals. The rats in Group 2 received 10 pmol 
AVP and 0.15 M NaCl, while the animals in Group 3 
received 100 pmol AVP and 0.15 M NaCl AICA infu- 
sions. Four animals in Groups 2 and 3 received the 
AVP infusion first, while the remaining four animals 
received the AVP infusion second. 
Experiment 3: Local AVP receptor antagonist pretreat- 
ment 
This experiment employed six animals, three of 
which received a 10 min AICA pretreatment infusion 
3 
of 0.15 M NaCl (100 nl/min) followed 10 min later by 
a 10 min infusion of AVP (100 pmol/lOO nl 0.15 M 
NaCl/min). Once base-levels were re-established these 
animals were then pretreated with a 10 min infusion of 
the AVP antagonist (10 nmol/lOO nlO.15 M NaCl/min) 
followed 10 min later by a 10 min infusion of AVP (100 
pmol/lOO nl 0.15 M NaCl/min). The other three ani- 
mals in this group received the antagonist pretreatment 
first and then the 0.15 M NaCl pretreatment second. 
Experiment 4: Local AVP-receptor antagonist pretreat- 
ment followed by AVP femoral artery infusions 
Eight animals were assigned to 2 groups (4 each). In 
each group, baselevel BP and CoBF were established 
during a 10 min period prior to each infusion. All 
animals received two separate infusions of AVP (10 
pmol/50 ~1 0.15 M NaCl/min for 10 min) via the 
femoral artery infusion catheter following a 10 min 
infusion of either 0.15 M NaCl or the AVP antagonist 
via the AICA. The animals in Group 1 received the 
AVP-specific antagonist at a dose of 1 nmol/lOO nl 
0.15 M NaCl/min while the members of Group 2 
received AVP antagonist at a dose of 2 nmol/lOO nl 
0.15 M NaCl/min. Two animals in Group 1 received 
the control pretreatment infusion first while the re- 
maining two animals received the antagonist infusion 
first. All members of Group 2 received the 0.15 M 
NaCl pretreatment infusion first. 
Statistical analysis 
Systemic blood pressure and CoBF were scored 
every 30 s throughout each pre-infusion, infusion, and 
post-infusion period in mm Hg and percent change 
from base-level, respectively. Differences in baselevel 
BP among groups used in Experiments l-4 were ana- 
lyzed via one-way analyses of variance (ANOVA). In 
Experiment 1, changes in BP and CoBF were analyzed 
by separate 5 (dose) x 10 (time points) repeated mea- 
sures ANOVAs. BP and SBF data taken from the 
additional animals of Experiment 1 were analyzed via 
separate 4 (dose) x 10 (time points) repeated measures 
ANOVAs. In Experiment 2, alterations in BP and 
CoBF during AICA infusions were analyzed via sepa- 
rate 3 (dose) x 10 (time points) repeated measures 
ANOVAs. In Experiment 3, changes in BP and CoBF 
during AICA pre-treatment and AVP infusions were 
analyzed via separate 1 (group) X 4 (treatments) 
ANOVAs. Post-hoc comparisons were made via subse- 
quent 1 (group) X 2 (treatments) ANOVAs. Changes in 
systemic BP and CoBF were measured during each 
pre-infusion and infusion period in Experiment 4. 
Base-level systemic BP for animals in this experiment 
were analyzed by a l-between ANOVA. Alterations in 
BP from baselevel during the 10 pmol femoral artery 
3 
infusions were analyzed via separate 2-within ANOVAs 
for each pretreatment condition. Differences in BP 
between groups during AVP infusions were analyzed 
via l-between, Z-within ANOVAs. Changes in BP and 
CoBF during the local AICA pretreatments were ana- 
lyzed via separate l-between, l-within ANOVAs. Com- 
parisons between mean percent changes in CoBF from 
base-levels during the 10 pmol AVP infusions were 
made by separate 2-within ANOVAs while compar- 
isons between groups (dose) were made via l-between 
l-within ANOVAs. Newman-Keuls tests were used to 
make post-hoc comparisons (P < 0.05). 
Results 
Experiment I: Effects of intra-arterial infusion of AW 
on CoBF 
There were no significant differences in mean anes- 
thetized baselevel BP among the 6 groups in this 
experiment. An overall mean (4SEM) baselevel anes- 
thetized BP of 102( + 2) mm Hg was observed for these 
animals. Fig. 2 presents the effects of intra-arterial 
infusion of increasing doses of arginine vasopressin on 
systemic blood pressure. Increases in BP were ob- 
served during the initial minutes of the AVP infusion 
periods and remained elevated for the duration of the 
infusion. Elevations in BP followed a significant dose- 
response pattern (F = 16.32, df = 36,315, P < 0.0001) 
with the higher doses of AVP yielding greater in- 
creases. The specific maximum mean (&SEMI BP in- 
creases observed during the infusions of 0, 0.1, 1, 10, 
and 100 pmol AVP were: 0.6( *0.3), 2.5( rt 0.3), 
9.3t10.71, 52.2 c&6.3), and 83.6ci4.4) mm Hg, respec- 
tively. Post-hoc analyses indicated that those animals 
that received the 1, 10, and 100 pmol doses displayed 
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Fig. 2. Mean (*SEM) changes in systemic blood pressure (mm Hg) 
from base-level during the 10 min carotid artery infusions of 0, 0.1, I, 
IO, and 100 pmol AVP/SO +I 0.15 M NaCl/min in the rat. Base-level 
mean (i SEM) anesthetized blood pressure was 100 + 2 mm Hg. 
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Fig. 3. Mean (i SEM) percent changes in CoBF from base-level 
during the 10 min carotid artery infusions of 0. 0.1, 1, 10, and 100 
pmol AVP/SO ~1 0.15 M NaCl/min in the rat. 
significant BP elevations as compared with the control 
group, while the 10 and 100 pmol doses differed from 
each other and from the other three groups. 
Fig. 3 illustrates the influence of increasing doses of 
intra-arterially infused AVP on CoBF. Although CoBF 
increased significantly during the infusion of the 100 
pmol dose of AVP (F = 3.04, df = 36, 315, P < O.OOOl>, 
no significant alterations in CoBF were observed dur- 
ing the infusion of any other dose of AVP. Respective 
mean (+ SEM) percent changes in CoBF for those 
groups that received the 0, 0.1, 1, 10, and 100 pmol 
doses were: -0.3 &0.4), -4.5 (*1.5), -2.9(+1.8), 
3.6t f 0.91, and 47.4( + 2.4)%. 
Fig. 4 presents the mean (+SEM) SBF responses 
during the infusion of 0, 1, 10, and 100 pmol AVP. 
These mean ( f SEMI SBF responses were significantly 
different (F = 31.84, df = 3,28, P < 0.0001). No alter- 
ations in SBF were measured during the 0.15 M NaCl 
infusions, however AVP infusions (1, 10, and 100 pmol) 
resulted in sustained decreases in SBF significantly 
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Fig. 4. Mean (+SEM) percent changes in SBF from base-level 
during the 10 min carotid artery infusions of 0, 1, 10, and 100 pmol 
AVP/SO ~10.15 M NaCl/min. 
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Fig. 5. Mean (k SEMI percent changes in CoBF from base-level 
during the AICA infusions of 0, 10 and 100 pmol AVP/lOO nl 0.15 
M NaCl/min. 
different from 0.15 M NaCl (Fs = 21.18, 45.3, and 73.3 
respectively, df = 1, 14, P < 0.0001). Additionally, post- 
hoc analyses indicated that each dose of AVP pro- 
duced SBF responses significantly different from the 
next. 
The alterations in SBF were accompanied by signifi- 
cant alterations in BP (mm Hg) very similar to those 
reported in Fig. 2. The mean (*SEMI pressor re- 
sponses to 0, 1, 10, and 100 pmol AVP were l( kO.11, 
9.8(+0.4), 52.ZXk5.61, and 74.8ck6.0) mm Hg, respec- 
tively (F = 100.6, df = 3,28, P < 0.0001). Post-hoc anal- 
yses revealed that each dose of AVP induced pressor 
responses different from 0.15 M NaCl infusion and 
from each other. 
Experiment 2: Anterior inferior cerebellar artery (AZCA) 
A VP infusion 
A mean (&SEM) anesthetized base-level BP of 
103( + 1.6) mm Hg was observed in the three groups of 
animals used in this experiment. Local AICA infusions 
of 0, 10, and 100 pmol AVP produced no significant 
alterations in systemic BP, however, Fig. 5 illustrates 
the mean (+SEM) percent changes in CoBF during 
AICA infusion of AVP. Dose-dependent decreases in 
CoBF were observed during the infusions of 10 and 
100 pmol doses of AVP with the highest AVP dose 
producing the largest reduction in CoBF. The mean 
( + SEM) percent changes in CoBF observed during the 
infusion of 0, 10, and 100 pmol AVP were 2.6(&0.5), 
- 8.5( + 0.5), and - 15.0( k 0.9)%, respectively, which 
were statistically different (F = 40.79, df = 2, 21, P < 
0.0001). Post-hoc comparisons indicated that the mean 
(f SEM) percent changes in CoBF of 0.5ck2.61, 
- 9.5( + 2.51, and - 16.3( & 0.81% observed during the 
last minute of the 0, 10, and 100 pmol AVP infusions, 
respectively, were significantly different from one an- 
other. 
Experiment 3: Local AI0 receptor antagonist pretreat- 
ment 
A mean (_t SEMI anesthetized BP of 100.8 (kO.2) 
mm Hg was observed in the animals used in this 
experiment. No significant alterations in BP were mea- 
sured during the AICA infusions of 0.15 M NaCl, 100 
pmol AVP, or the AVP antagonist. Fig. 6 illustrates 
the mean (k SEM) percent change in CoBF during 
infusion of AVP following pretreatment with 0.15 M 
NaCl or the AVP antagonist. The 0.15 M NaCl pre- 
treatment did not affect the subsequent mean ( _t SEM) 
AVP-induced reductions in CoBF of 17.4 c&3.4)%; 
however, pretreatment with the receptor antagonist 
abolished the AVP-induced reductions in CoBF, yield- 
ing a mean (*SEM) percent change in CoBF of 
+ 1.2( + 0.41%. These values were significantly differ- 
ent (F = 26.30, df = 3, 15, P < 0.0001). 
Experiment 4: Local AW-receptor antagonist pretreat- 
ment followed by AW femoral artery infusions 
A mean (f SEM) anesthetized systemic BP of 125 
( f 1.0) mm Hg was observed in the animals of Experi- 
ment 4. No significant alterations in BP or CoBF were 
observed during any of the AICA pretreatment infu- 
sions. Following the 0, 1, and 2 nmol pretreatment 
doses of the AVP antagonist, the subsequent 10 pmol 
dose of AVP via the femoral artery catheter produced 
significant mean (5 SEM) increases in BP of 
70.1(+5.2), 68.2(+3.3), and 74.0(&4.3) mm Hg, re- 
spectively (Fs = 124.50, 347.37, and 182.55 respectively, 
df = 1, 3, P < 0.001). 
Figure 7 presents the mean ( + SEMI percent change 
in CoBF during femoral artery infusion of AVP follow- 
ing the 10 min 0, 1, and 2 nmol AVP antagonist AICA 
pretreatment infusions. It can be seen that CoBF slowly 
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Fig. 6. Mean (+ SEM) percent changes in CoBF from base-level 
during 10 min AICA infusions of AVP (100 pmol/lOO nl 0.15 M 
NaCl/min) following a 10 min pretreatment with either the AVP- 
specific receptor antagonist or 0.15 M NaCI. 
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Fig. 7. Mean (+ SEM) percent changes in CoBF during the femoral 
artery infusions of AVP (10 pmol/50 ~1 0.15 M NaCl/min) follow- 
ing local AVP antagonist (0, 1 and 2 nmol/lOO nl 0.15 M NaCl/min) 
pretreatments. 
increased during the AVP femoral artery infusions that 
had been preceded by the local AVP antagonist pre- 
treatments and then slowly decreased toward base- 
level; however, BP remained elevated throughout the 
AVP femoral artery infusion periods. Significant mean 
percent increases in CoBF were observed only during 
the AVP infusions following pretreatment with the 
antagonist (1 and 2 nmol) via local infusion (F = 62.66, 
df = 1, 3, P < 0.004), and (F = 35.22, df = 1, 3, P < 
0.009), respectively. Maximum mean ( + SEM) percent 
increases in CoBF were 7.9( f 1.9), 32.0( + 4.0), and 
40.0( &- 5.2)% following the 0, 1, and 2 nmol antagonist 
pretreatment conditions measured during AVP infu- 
sion, respectively. Although slightly higher increases in 
CoBF were observed following the 2 nmol antagonist 
pretreatment, these increases were not significantly 
different from those observed following the 1 nmol 
antagonist infusion. 
An order effect was observed in this experiment. In 
general, increases in CoBF were greater than expected 
during control infusions if the antagonist was adminis- 
tered prior to the control condition. Therefore, the 
antagonist (2 nmol) was administered last to the ani- 
mals of Group 2. 
Discussion 
Autoregulation in cerebral vessels has been con- 
firmed (e.g., Baumbach and Heistad, 1985) and sug- 
gested as a model system for investigating CoBF 
(Lawrence et al., 1977; Miller et al., 1983; Miller and 
Dengerink, 1988). The hypothesis that CoBF is under 
local autoregulatory control has been proposed by sev- 
eral authors (Dengerink et al., 1985; Flynn et al., 1988; 
Hultcrantz et al., 1982: La Rouere et al., 1989; Miller 
et al., 1983, 1984; Quirk et al., 1988, 1989), and was 
recently confirmed by Quirk et al. (1989) in the rat. 
These investigators (Quirk et al., 1989) intra-arterially 
infused angiotensin II or phenylephrine in order to 
produce elevations in systemic blood pressure and 
measured initial elevations in CoBF followed by a slow 
recovery of base-level CoBF despite sustained eleva- 
tions in blood pressure. In a companion experiment, 
AI1 was infused into the AICA and resulted in signifi- 
cant reductions in CoBF without altering systemic blood 
pressure. If the AICA was pretreated with an AI1 
receptor antagonist, these AII-induced reductions in 
CoBF were blocked. These results suggested that an- 
giotensin receptors are present in the cochlear vascula- 
ture and could be activated by blood-borne AI1 result- 
ing in vasoconstriction. As previously indicated, AI1 
receptors have now been identified in the cochlear 
vasculature of young rats using autoradiographic tech- 
niques (Coleman et al., submitted; Cook et al., submit- 
ted). 
The results from the present investigation confirmed 
our expectation that exogenous infusion of arginine 
vasopressin would produce vasoactive effects in the 
cochlea. The results from local infusion of AVP and an 
AVP-specific receptor antagonist into the AICA sug- 
gest that an AVP receptor population may be present 
in the vessels directly supplying the cochlea or possibly 
in those vessels housed within the otic capsule. This 
receptor population may be capable of mediating a 
vasocontractile response. Additionally, the results from 
AICA pretreatment with an AVP antagonist followed 
by femoral artery AVP infusions suggest that AVP and 
its vascular receptors may participate in tonic control 
of CoBF during AVP-induced elevations in systemic 
blood pressure, however, this tonic control may be 
overcome by an elevation of 60 mm Hg or greater in 
systemic blood pressure. Presently, there is no avail- 
able information confirming the presence of AVP re- 
ceptors in the cochlear microvasculature, however, our 
laboratory has initiated such an investigation utilizing 
autoradiographic techniques. 
Angiotensin II and AVP are clearly not the only 
vasoactive ligands present in the cochlear vasculature. 
The autonomic nervous system innervates the cochlea 
(Lorente de No, 1937; Smith, 1951) providing adrener- 
gic fibers that make contact with vessels of the inner 
ear such as the spiral modiolar artery (Spoendlin and 
Lichtensteiger, 1966) and vessels of the osseous spiral 
lamina and tympanic lip (Brechtelsbauer et al., 1990). 
Although innervation has been confirmed by electron 
microscopy (Densert, 1974; Densert and Flock, 1974; 
Prazma et al., 1990), little is known about the contribu- 
tion these fibers may make to regulation of CoBF. The 
potential role of peptides in CoBF is even less well 
understood. Matsuyama et al. (1986), using immunohis- 
tochemical techniques, reported the presence of sub- 
stance P, calcitonin gene-related peptide, vasoactive 
intestinal polypeptide, and neuropeptide Y-like fibers 
in the basilar artery of the guinea pig and rat. More 
recently, Carlisle et al. (19901 reported the presence of 
fibers for these same peptides along the length of the 
guinea pig spiral modiolar artery using immunofloures- 
cent and histofluorescent techniques. These results 
suggest that there may be vascular receptors for these 
compounds in the SMA as well. 
Several conclusions can be drawn from the results of 
the present experiments. First, intra-carotid artery in- 
fusion of AVP yielded dose-related elevations in sys- 
temic blood pressure with increases in CoBF noted 
only with the highest dose of AVP administered (100 
pmol). Significant elevations in systemic blood pressure 
were observed during the 10 pmol AVP infusion, how- 
ever, no alterations in CoBF were associated with this 
pressure increase. Such a pattern of CoBF responses 
would be expected if CoBF were under local control. 
Second, the intra-carotid infusion of AVP yielded sig- 
nificant reductions in skin blood flow. These results 
suggest that blood flow to peripheral tissues such as 
the skin may be compromised during periods of height- 
ened systemic blood pressure induced by infusion of 
exogenous AVP. Third, infusion of AVP into the AICA 
produced dose-related reductions in CoBF with no 
alterations in systemic blood pressure. Pretreatment of 
the cochlear supplying vessels with an AVP-specific 
receptor antagonist significantly attenuated these re- 
ductions thus linking this vasocontractile response to 
the interaction of AVP with a population of vascular 
AVP receptors in the cochlea or its supplying vessels. 
Fourth, intra-arterial infusion of the 10 pmol dose of 
AVP significantly elevated BP with no associated alter- 
ation in CoBF (Experiment 1); however, if this infusion 
was preceded by a local AICA infusion of an AVP- 
specific V, receptor antagonist, significant elevations in 
both systemic BP and CoBF were measured (Experi- 
ment 4). These results suggest that vascular receptors 
may contribute to tonic control (i.e., autoregulation) of 
CoBF during elevations in systemic BP, however, this 
tonic control may be overcome by increases of 60 mm 
Hg or greater in blood pressure which forces an in- 
crease in CoBF, or by delivering the ligand directly into 
the cochlear vasculature which presumably decreases 
the exposure time to blood peptidase activity, resulting 
in reductions in CoBF, or by blocking these receptors 
with an AVP antagonist. 
In sum, these results further support the hypothesis 
that peptide receptors are present in the vasculature of 
the cochlea and that activation of these receptors by 
blood-borne peptides (e.g. AI1 and AVP) may play a 
role in the regulation of CoBF. The present findings, 
coupled with previous work from our laboratory (De- 
ngerink et al., 1986; Quirk et al., 1988, 1989), support 
an autoregulatory model of cochlear blood flow which 
may in part be mediated by the interaction of circulat- 
ing vasoactive peptides with their vascular receptor 
populations in the vessels supplying the inner ear. 
Further, confirmation of this hypothesis must await 
demonstration that peptide receptor populations, in 
addition to angiotension II, are in fact present in these 
cochlear vessels. 
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